RT Journal Article
SR Electronic
T1 Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.07.21260122
DO 10.1101/2021.07.07.21260122
A1 Li, Baisheng
A1 Deng, Aiping
A1 Li, Kuibiao
A1 Hu, Yao
A1 Li, Zhencui
A1 Xiong, Qianling
A1 Liu, Zhe
A1 Guo, Qianfang
A1 Zou, Lirong
A1 Zhang, Huan
A1 Zhang, Meng
A1 Ouyang, Fangzhu
A1 Su, Juan
A1 Su, Wenzhe
A1 Xu, Jing
A1 Lin, Huifang
A1 Sun, Jing
A1 Peng, Jinju
A1 Jiang, Huiming
A1 Zhou, Pingping
A1 Hu, Ting
A1 Luo, Min
A1 Zhang, Yingtao
A1 Zheng, Huanying
A1 Xiao, Jianpeng
A1 Liu, Tao
A1 Che, Rongfei
A1 Zeng, Hanri
A1 Zheng, Zhonghua
A1 Huang, Yushi
A1 Yu, Jianxiang
A1 Yi, Lina
A1 Wu, Jie
A1 Chen, Jingdiao
A1 Zhong, Haojie
A1 Deng, Xiaoling
A1 Kang, Min
A1 Pybus, Oliver G.
A1 Hall, Matthew
A1 Lythgoe, Katrina A.
A1 Li, Yan
A1 Yuan, Jun
A1 He, Jianfeng
A1 Lu, Jing
YR 2021
UL http://medrxiv.org/content/early/2021/07/12/2021.07.07.21260122.abstract
AB We report the first local transmission of the Delta SARS-CoV-2 variant in mainland China. All 167 infections could be traced back to the first index case. The investigation on daily sequential PCR testing of the quarantined subjects indicated the viral load of the first positive test of Delta infections was ∼1000 times higher than that of the 19A/19B strains infections back in the initial epidemic wave of 2020, suggesting the potential faster viral replication rate and more infectiousness of the Delta variant at the early stage of the infection. The 126 high-quality sequencing data and reliable epidemiological data indicated some minor intra-host single nucleotide variants (iSNVs) could be transmitted between hosts and finally fixed in the virus population during the outbreak. The minor iSNVs transmission between donor-recipient contribute at least 4 of 31 substitutions identified in the outbreak suggesting some iSNVs could quickly arise and reach fixation when the virus spread rapidly. Disease control measures, including the frequency of population testing, quarantine in pre-symptomatic phase and enhancing the genetic surveillance should be adjusted to account for the increasing prevalence of the Delta variant at global level.Competing Interest StatementThe views expressed in this article are those of the authors and not necessarily those of the Guangdong Provincial Center for Diseases Control and Prevention, or the Guangdong Provincial Institute of Public Health.Funding Statement1.Science and Technology Planning Project of Guangdong (2018B020207006) 2.The Key Research and Development Program of Guangdong Province (2019B111103001) 3.Guangdong Workstation for Emerging infectious Disease Control and Prevention, Chinese Academy of Medical Sciences (2020-PT330-004)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional ethics committee of the Guangdong Provincial Center for Disease Control and Prevention (GDCDC). Written consent was obtained from patients or their guardian(s) when samples were collected. Patients were informed about the surveillance before providing written consent, and data directly related to disease control were collected and anonymized for analysis. For immunity evaluation, serum samples were collected from vaccinated volunteers in GDCDC with written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSome or all data, models, or code generated or used during the study are proprietary or confidential in nature and may only be provided with restrictions.